Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation

Cancer Immunology Immunotherapy

Volumn 43, Issue 4, 1996, Pages 206-212

  Ino, Kazuhiko ^a   Bierman, Philip J ^a   Varney, Michelle L ^a   Heimann, Dean G ^a   Kuszynski, Charles A ^a   Walker, Sheryl A ^a   Talmadge, James E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

autologous BMT; bestatin; immunomodulator; lymphoma; monocyte activation

Indexed keywords

BESTATIN; CD14 ANTIGEN; HLA DR ANTIGEN; NEOPTERIN;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; LYMPHOMA; MALE; MONOCYTE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADULT; AGED; BIOPTERIN; BONE MARROW TRANSPLANTATION; COLONY-STIMULATING FACTORS; COMBINED MODALITY THERAPY; FEMALE; HLA-DR ANTIGENS; HUMANS; LEUCINE; LYMPHOMA, NON-HODGKIN; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; NEOPTERIN; RECEPTORS, IGG;

EID: 0030451274     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050323     Document Type: Article

References (53)

1. Abe F, Hayashi M, Horinishi H, Matsuda A, Ishizuka M, Umezawa H (1986) Enhancement of graft-versus-host reaction and delayed cutaneous hypersensitivity in mice by ubenimex. J Antibiot (Tokyo) 39:1172
2. Abe F, Alvord G, Koyama M, Matsuda A, Talmadge JE (1989) Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases. Cancer Immunol Immunother 28:29
3. Abe F, Schneider M, Black PL, Talmadge JE (1989) Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice. Cancer Immunol Immunother 29:231
4. Abe F, Matsuda A, Schneider M, Talmadge JE (1990) Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice. Cancer Immunol Immunother 32:75
5. Aoki I, Higashi K, Nishijima K, Homori M, Chikazawa H, Ishikawa K (1991) Effects of ubenimex on erythroid progenitors (CFU-E and BFU-E) in human bone marrow.Exp Hematol 19:893
6. Ashmun RA, Look AT (1990) Metalloprotease activity of CD13/ aminopeptidase N on the surface of human myeloid cells. Blood 75:462
7. Blau N, Schoedon G, Curtius H-C (1989) Biosynthesis and significance of neopterin in the immune system. Eur J Cancer Clin Oncol 25:603
8. Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G, Montesoro E, Mastroberardino G, Isacchi G, Testa U, Calabresi F, Peschle C (1990) Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res 50:5795
9. Clarkson SB, Ory PA (1988) CD16: Developmentally regulated IgG Fc receptors on cultured human monocytes. J Exp Med 167:408
10. Entringer MA, Robinson W A, Drebing CJ (1980) Colony stimulating activity in normal human serum tested against human bone marrow. Exp Hematol 8:1232
11. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H (1988) Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 9:150
12. Henderson DC, Sheldon J, Riches P, Hobbs JR (1991) Cytokine induction of neopterin production. Clin Exp Immunol 83:479
13. Hiraoka A, Shibata H, Masaoka T.Immunopotentiation with ubenimex for prevention of leukemia relapse after allogeneic BMT. Transplantaion Proc 24:3047
14. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H (1984) Immune response-associated production of neopterin: Release from macrophages primarily under control of interferon-gamrna. J Exp Med 160:310
15. Ishizuka M, Sato J, Sugiyama Y, Takeuchi T, Umezawa H (1980) Mitogenic effect of bestatin on lymphocytes. J Antibiot (Tokyo) 33:653
16. Jarstrand C, Blomgren H (1982) Influence of bestatin a new immunomodulator on various functions of human monocytes. J Clin Lab Immunol 9:193
17. Joffe JK, Bell JBG, Denham S, Adshead F, Millar JL, Millar BC (1995) G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM). Exp Hematol 23:376
18. Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, Weisenburger DD (1989) High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 74:1260
19. Klingemann H-G (1995) Introducing graft-versus-leukemia into autologous stem cell transplantation. J Hematother 4:261
20. Klingemann H-G, Phillips GL (1991) Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 8:73
21. Kohn FR, Phillips GL, Klingemann H-G (1992) Regulation of tumor necrosis factor-a production and gene expression in monocytes. Bone Marrow Transplant 9:369
22. Koyama M. (1987) Pharmacokinetics and biotransformation of Bestatin. In: Umezawa H (ed) Recent results of bestatin. Japanese Antibiotic Research Association Tokyo, pp 41
23. Levy PC, Looney RJ, Shen L, Graziano RF, Fanger MW, Roberts NJ, Ryan DH, Utell MJ (1990) Human alveolar macrophage FcR-mediated cytotoxicity: heteroantibody- versus conventional antibody-mediated target cell lysis. J Immunol 144:3693
24. Leyhausen G, Gramzow M, Zahn RK, Steffen R, Umezawa H, Müller WEG (1983) Immunochemical identification of the cell surface bound leucine aminopeptidase, the target enzyme for the immunostimulant bestatin. J Antibiot (Tokyo) 36:728
25. Millar BC, Bell JBG, Millar JL, Treleaven J, Montes A, Joffe JK, Powles RL, McElwain TJ (1992) Colony-stimulating activity in the serum of patients with hemopoietic malignancies after intensive chemotherapy/radiotherapy: its augmentation by GM-CSF in vivo and interleukin 4 in vitro.Exp Hematol 20:209
26. Müller WEG, Schuster DK, Zahn RK, Maidhof A, Leyhausen G, Falke D, Koren R, Umezawa H (1982) Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. Int J Immunopharmacol 4:393
27. Munn DH, Cheung NKV (1989) Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. J Exp Med 170:511
28. Niederwieser D, Huber C, Gratwohl A, Bannert P, Fuchs D, Hausen A, Reibnegger G, Speck B, Wachter H (1984) Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation 38:497
29. Niederwieser D, Herold M, Woloszczuk W, Aulitzky W, Meister B, Tilg H, Gastl G, Bowden R, Huber C (1990) Endogenous IFN-gamma during human bone marrow transplantation: analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 50:620
30. Noma T, Klein B, Cupissol D, Yata J, Serrou B (1984) Increased sensitivity of IL2-dependent cultured T cells and enhancement of in vitro IL2 production by human lymphocytes treated with bestatin. Int J Immunopharmacol 6:87
31. Ohhara N, Okamura S, Niho Y, Otsuka T (1985) Stimulatory effect of aminopeptidase inhibitor on human bone marrow CFU-C mediated by the interaction of T-lymphocytes Acta Haematol Jpn 48:1012-1016
32. Okamura S, Omori F, Haga K, Baba H, Sugimachi K, Niho Y (1990) Influence of bestatin on production of granulocyte-macrophage colony-stimulating factor from human peripheral blood mononuclear cells in vitro.Acta Oncol 29:795
33. Okura A, Ishizuka M, Takeuchi T (1988) Effect of ubenimex on the production of murine interferon. J Antibiot (Tokyo) 41:261
34. Ota K (1991) Review of ubenimex (bestatin): clinical research. Biomed Pharmacother 45:55
35. Ota K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N (1986) Immunotherapy with bestatin for acute nonlymphocytic-leukemia in adults. Cancer Immunol Immunother 23:5
36. Otsuka T, Okamura S, Ohhara N, Harada M, Hayashi S, Yamaga S, Omori F, Niho Y (1988) Stimulatory effect of bestatin on human B-cell colony formation. Int J Immunopharmacol 10:587
37. Passlick B, Flieger D, Ziegler-Heithrock HWL (1989) Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 74:2527
38. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Chan J-Y, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte J-P, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493
39. Phillips GL, Fay JW, Herzig RH, Lazarus,HM, Wolff SN, Lin H, Shina DC, Glasgow GP, Griffith RC, Lamb CW, Herzig GP (1990) The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 75:831
40. Rivier A, Pene J, Rabesandratana H, Chanez P, Bousquet J, Campbell AM (1995) Blood monocytes of untreated asthmatics exhibit some features of tissue macrophage. Clin Exp Immunol 100:314
41. Schorlemmer HU, Bosslet K, Sedlacek HH (1983) Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes. Cancer Res 43:4148
42. Shibuya K, Hayashi E, Abe F, Takahashi K, Horinishi H, Ishizuka M, Takeuchi T, Umezawa H (1987) Enhancement of interleukin 1 and interleukin 2 releases by ubenimex. J Antibiot (Tokyo) 40:363
43. Shibuya K, Chiba S, ino M, Kitamura T, Miyagawa K, Takaku F, Miyazano K (1991) Enhancing effect of ubenimex (bestatin) on proliferation and differentiation of hematopoietic progenitor cells and the suppressive effect on proliferation of leukemic cell lines via peptidase regulation. Biomed Pharmacother 45:71
44. Steis RG, VanderMolen LA, Longo DL, Clark JW, Smith JW, Kopp WC, Ruscetti FW, Creekmore SP, Elwood LJ,Hursey J, Urba WJ (1990) Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: A phase Ib trial. J Natl Cancer Inst 82:697
45. Suda H, Aoyagi T, Takeuchi T, Umezawa H (1976) Inhibition of aminopeptidase B and Leucine aminopeptidase by bestatin and its stereoisomer. Arch Biochem Biophys 177:196
46. Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, Tribble H (1986) Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res 46:4505
47. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL, Mills KC, Thomas ML, Pirruccello SJ, Letheby BA, Arneson MA, Jackson JD (1996) Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 17:101
48. Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T (1976) Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot (Tokyo) 29:97
49. Umezawa H, Ishizuka M, Aoyagi T, Takeuchi T (1976) Enhancement of delayed-type hypersensitivity by bestatin an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo) 29:857
50. Urabe A, Mutoh Y, Mizoguchi H, Takaku F, Ogawa N (1993) Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann Hematol 67:63
51. Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, Alpaugh RK (1994) Phase I trial of recombinant macrophage colony-stimulating factor and recombinant γ-interteron: Toxicity monocytosis and clinical effects. Cancer Res 54:4084
52. Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE, Borden EC (1993) Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 53:5176
53. Yamasaki K, Solberg LA, Jamal N, Lockwood G, Tritchler D, Curtis JE, Minden MM, Mann KG, Messner HA (1988) Hemopoietic colony growth-promoting activities in the plasma of bone marrow transplant recipients. J Clin Invest 82:255